Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $20, while Vertex Pharmaceuticals Incorporated trades at $473.69 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $103.20 | $529.59 |
52-Week Low | $18.43 | $366.54 |
Market Cap | — | $120.89B |
Enterprise Value | — | $115.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.
The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
